Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection

Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection

This study aims to compare the effectivity between ondansetron 8 mg and lidocain 40 mg in preventing pain due to propofol injection

Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study. Non-invasive blood pressure (NIBP) monitor, ECG and pulse-oximeter was set on the subjects in the operation room. After a tourniquet made from NIBP cuff were inflated, subjects were given either Ondansetron 8 mg or Lidocain 20 mg intravenously, then the tourniquet was set off. Hemodynamic data was recorded. Propofol 1 mg/kg of body weight (BW) injection was given. Verbal rating scale was used to measure pain at 0 s, 5 s and 30 s. Data was analyzed using Statistical Package for the Social Sciences (SPSS), for numeric data using uni-variate analysis and bi-variate analysis. Significant value is p<0.05.

Inclusion Criteria:

• Subjects aged 18-65 years old
• Subjects were planned to undergo general anesthesia with propofol
• Subjects with Body Mass Index (BMI) 18-35 kg/m2
• Subjects with American Society of Anesthesiologists (ASA) physical status of I-II
• Subjects with signed informed consent.

Exclusion Criteria:

• Subjects with allergies to propofol, lidocain, ondansetron
• Subjects with massive cardiac disorder
• Subjects with cardiac rhythm disorder with or without treatment
• Subjects with unstable hemodynamic
• Subjects with contraindication to propofol, lidocain, ondansetron
• Subjects with intubation and ventilation difficulty
• Subjects with decreased consciousness, seizure history or head injury
• Subjects with analgesic treatment history
• Subjects with pregnancy.

Drop out criteria:

• Subjects with allergic reactions induced by propofol, lidocain, ondansetron
• Uncooperative subjects
• Subjects in emergency
• Subjects with difficult vein access in the dorsum manus
• Subjects with infection and/or inflammation in the planned intravenous cannulation location.